


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Defitelio is a medication formulated as an intravenous injection containing defibrotide sodium, primarily used for managing hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT). VOD is a serious condition characterized by the obstruction of small veins in the liver, which may lead to hepatic dysfunction and multi-organ failure. This drug is particularly crucial in cases where VOD is accompanied by renal or pulmonary complications.
The mechanism of action of Defitelio is not fully elucidated in the document; however, it is known to exert its therapeutic effects by improving endothelial function and protecting vascular integrity, making it a vital intervention in critically ill post-transplant patients. The treatment protocol typically involves administering a 6.25 mg/kg dose every 6 hours through a 2-hour intravenous infusion for a minimum of 21 days, with continued treatment if symptoms persist.
DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), who develop renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
Recommended Dosage: The recommended dose is 6.25 mg/kg administered every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient’s baseline body weight (prior to the HSCT preparative regimen).
Duration of Treatment: Treat for a minimum of 21 days. If signs and symptoms of VOD have not resolved after 21 days, continue treatment until resolution or up to a maximum of 60 days.
